Jagsonpal Pharma FY26: Revenue ₹2,872 mn, PAT ₹446 mn

Jagsonpal Pharmaceuticals Limited announced its annual report for FY 2025-26, detailing a revenue of ₹2,872 million and operating PAT of ₹446 million, with an operating EBITDA of ₹609 million. The company reported a 7% revenue growth and 19% operating PAT growth for the fiscal year. The 47th Annual General Meeting (AGM) is scheduled for September 18, 2026, to be held via Video Conferencing. The report also highlights a ₹400 million share buyback completed during the year and a declared 200% dividend, including a special dividend of 75%. The record date for dividend payment is September 04, 2026.